Posts

Topical Hair Loss Treatments Market 2018

Improved Minoxidil Formulation Safe, Effective for Androgenetic Alopecia

Improved Minoxidil Formulation Safe, Effective for Androgenetic Alopecia

The results of the study demonstrated that DC0120 was noninferior to the comparator agent.

A new formulation of minoxidil (DC0120; Pierre-Fabre Dermatologie) with improved cosmetic characteristics is noninferior to a comparator minoxidil product (Alostil; Johnson & Johnson) for the stimulation of hair growth among men with androgenetic alopecia (AGA).

Results from the phase 2, multicenter, randomized, placebo-controlled, double-blind study conducted at 4 sites in Germany were published in the Journal of Cosmetic Dermatology.

In each of the participants, 2 10-cm2 areas on the scalp were randomly assigned to receive DC0120, the comparator agent, or 1 of 2 corresponding vehicles, with each applied 2 times daily for 16 weeks.

Measurements of nonvellus target area hair count (TAHC) within the treatment area were obtained at baseline and after 8 weeks and 16 weeks, by digital phototrichogram.

A total of 220 individuals with AGA were included in the analysis, with 210 completing the study. Overall, there were 110 patients in the DC0120 arm, 44 in the DC0120-comparator arm, 44 in the comparator-DC0120 vehicle arm, and 22 in the DC0120-vehicle comparator arm.

The mean age of the participants was 41.5±10.9 years (range, 19 to 62 years).

The results of the study demonstrated that DC0120 was noninferior to the comparator agent. Compared with the vehicle groups, both minoxidil treatments increased nonvellus TAHC at 8 weeks and 16 weeks. No new safety concerns were revealed.

The investigators concluded that DC0120 is as efficacious and safe as a similar marketed minoxidil agent for the stimulation of hair growth among men with AGA. They do indicate, however, that because the products used in this study were applied to small treatment areas rather than to the entire scalp, the study was not of sufficient size to determine less common adverse events.

Source

Reference
Blume-Peytavi U, Issiakhem Z, Gautier S, et al. Efficacy and safety of a new 5% minoxidil formulation in male androgenetic alopecia: a randomized, placebo-controlled, double-blind, noninferiority study [published online April 16, 2018]. J Cosmet Dermatol. doi: 10.1111/jocd.12541

Hair Loss Drug Minoxidil Might Improve Vascular Health

Topical Hair Loss Treatments Market 2018

Hair Loss Drug Minoxidil Might Improve Vascular Health

Hair Loss Drug Might Improve Vascular Health

Minoxidil, a popular drug used on the scalp to treat hair loss, might improve blood flow to the brain, lower blood pressure and increase elasticity in the blood vessels if taken in an oral form, according to a new study in mice. The article is published ahead of print in the American Journal of Physiology—Heart and Circulatory Physiology.

Elastin, an elastic protein found in connective tissue throughout the body, makes the blood vessels flexible. A lack of elastin causes stiffening of the blood vessels and arteries (vascular stiffness) and reduces blood flow. Vascular stiffness increases the risk of heart attack and stroke in aging adults. Reduced blood flow to the brain can contribute to age-related cognitive decline.

Previous studies have found that drugs that open the potassium channels—which allow potassium to exit the cells in the blood vessels—might improve blood flow. In the current study, researchers used a mouse model of congenital elastin insufficiency—the rare condition of being born with abnormally low levels of elastin—to determine how minoxidil, a type of potassium channel opener, improves vascular health.

People with congenital elastin insufficiency often need to take medication to control blood pressure and are at a higher risk for developing heart problems.

The research team divided the low elastin mice into three groups:

  • One group drank water mixed with oral minoxidil for two months (“treated”);
  • Another group was treated for two weeks before being removed from the medication (“partially treated”); and
  • A third group was not treated with the medication (“control”).

When compared to control mice, the treated mice had:

  • lower systolic blood pressure (pressure in the arteries when the heart beats);
  • larger, more open blood vessels such as the aorta and carotid artery;
  • lower vascular stiffness;
  • increased blood flow through the carotid arteries and into the brain; and
  • higher levels of an amino acid found in elastin.

These changes suggest that minoxidil changes the structure of the blood vessels to facilitate increased flexibility and blood flow.

The beneficial arterial changes were noticeable in the partially treated mice and were more obvious with longer treatment.  The changes remained for several weeks after the treated group was removed from the medication. The long-lasting results suggest that minoxidil might be used as a temporary treatment for vascular stiffness without the need for ongoing therapy.

minoxidil market report

“These results in mice are promising,” said Beth Kozel, MD, PhD, the senior author for the study, “We are looking forward to future clinical trials to test how this medication impacts blood flow in people.”

“Although studied here in a rare disease model, the implications of these findings for the treatment of vessels impacted by age-induced vascular stiffness and secondary elastin insufficiency are also important,” the researchers wrote. “Treatment of aged individuals with minoxidil may simultaneously improve blood pressure, arterial stiffness and blood flow—all risk factors for cardiovascular mortality, but also for long-term cognitive function.”

Read the full article, “Minoxidil improves vascular compliance, restores cerebral blood flow and alters extracellular matrix gene expression in a model of chronic vascular stiffness,” published ahead of print in the American Journal of Physiology—Heart and Circulatory Physiology.

Source

Minoxidil Market Report